Wegovy (semaglutide) is one of the most established and widely used prescription weight loss treatments available in the UK, with a comprehensive clinical trial programme and years of real-world prescribing experience behind it. It has generated significant interest from patients who want to understand how it works, what it costs, and who it is suitable for. At J E Williamson Pharmacy in Bishops Stortford, our Weight Loss Clinic provides fully supported, properly assessed Wegovy treatment for eligible patients. This page covers everything you need to know before booking a consultation. It includes pricing, doses, the injection device, expected results, safety considerations, and how to access treatment privately or through the NHS.
Book a Wegovy consultation at J E Williamson Pharmacy in Bishops Stortford today. Our clinical team will assess your suitability and help you start treatment with the right support in place from the very first dose.
Key takeaways
- Wegovy (semaglutide) is an MHRA-licensed prescription weight loss treatment that activates GLP-1 receptors in the brain and gut to reduce appetite, slow gastric emptying, and improve blood sugar regulation, producing a significant and sustained reduction in hunger that supports meaningful weight loss over time.
- Wegovy is available in five dose strengths from 0.25mg to 2.4mg, introduced gradually through a titration schedule that maintains each dose for a minimum of four weeks before escalation to minimise gastrointestinal side effects during the adjustment period.
- The Wegovy FlexTouch pen is a pre-filled multi-dose device containing four once-weekly doses, requiring a compatible disposable needle to be attached before each injection and removed and safely disposed of in a sharps container immediately afterwards.
- Wegovy is generally suitable for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition, and requires a thorough clinical assessment confirming individual suitability before any prescription can be issued.
- Private Wegovy treatment at J E Williamson Pharmacy in Bishops Stortford provides eligible patients with immediate access to a fully assessed, properly supported treatment programme without the waiting times associated with NHS specialist weight management services.
- Wegovy works most effectively when combined with meaningful dietary and lifestyle changes, and the quality of clinical support received throughout treatment is one of the most important determinants of the pace, magnitude, and sustainability of results.
What is Wegovy?
Wegovy is the brand name for semaglutide at a dose specifically developed and MHRA-licensed for weight management in adults with obesity or overweight alongside at least one weight-related health condition. It belongs to a class of medications known as GLP-1 receptor agonists. These medications mimic the action of a naturally occurring hormone called glucagon-like peptide-1, which plays a key role in regulating appetite, gastric emptying, and blood sugar levels.
Semaglutide was originally developed and licensed for the treatment of type 2 diabetes under the brand name Ozempic. Wegovy is a separate product containing semaglutide at a higher dose, developed specifically for weight management rather than diabetes treatment. The two products are not interchangeable. Wegovy should only be used by patients for whom it has been specifically prescribed following a thorough clinical assessment confirming their suitability for the weight management indication.
Wegovy is available in two forms in the UK. The injectable form uses the Wegovy FlexTouch pen, a pre-filled multi-dose device. The oral form of Wegovy received MHRA approval in June 2026. It is a once-daily tablet that must be taken on an empty stomach with a small amount of water. It should be taken at least thirty minutes before food or other oral medications. This page focuses primarily on the injectable form, which has the most extensive clinical evidence base and real-world prescribing experience. Both forms are available through J E Williamson Pharmacy in Bishops Stortford for eligible patients following a thorough clinical assessment.
How Wegovy Works
After each weekly injection, Wegovy enters the bloodstream and begins activating GLP-1 receptors in the brain and gut. In the brain, this activation reduces appetite and diminishes the psychological drive to eat beyond genuine hunger. In the gut, it slows the rate at which food leaves the stomach, prolonging the feeling of fullness after meals. This reduces the frequency with which hunger returns between eating occasions. It also has a beneficial effect on blood sugar regulation, which is particularly relevant for patients with type 2 diabetes or insulin resistance alongside their weight management goals.
The result of these combined effects is a significant and sustained reduction in appetite. Maintaining the calorie deficit needed for weight loss becomes considerably more manageable than dietary effort alone. Many patients describe Wegovy as the first time they have been able to eat in response to genuine hunger. Previously, habitual, emotional, or environmental triggers drove overconsumption in ways that dietary effort alone could not reliably address. This shift in the experience of food and hunger is one of the most consistently reported aspects of GLP-1 treatment. It underpins much of the long-term behaviour change that makes results sustainable beyond the period of active treatment.
Wegovy works most effectively when combined with meaningful dietary and lifestyle changes. The medication creates the conditions in which eating less becomes more manageable. What the patient does within those conditions directly determines the magnitude and sustainability of their results. Patients who make active improvements to their diet and increase their physical activity alongside Wegovy consistently achieve better outcomes. Managing stress and improving sleep quality alongside the medication also contribute meaningfully to overall results.
Do you want to understand whether Wegovy is the right treatment for your individual circumstances? The clinical team at J E Williamson Pharmacy in Bishops Stortford is ready to help. Contact us today for a personalised, evidence-based assessment.
Wegovy Price at J E Williamson Pharmacy
The cost of private Wegovy treatment varies depending on the dose strength, as each dose level is priced differently. Each Wegovy FlexTouch pen contains four once-weekly doses, covering one month of treatment at any given dose level. The cost therefore changes as the titration schedule progresses and dose levels increase. Our current pricing is set out below.
- One-off consultation fee: £25
- 0.25mg: £146 per pen (four weekly doses)
- 0.5mg: £146 per pen (four weekly doses)
- 1mg: £196 per pen (four weekly doses)
- 1.7mg: £250 per pen (four weekly doses)
- 2.4mg: £350 per pen (four weekly doses)
These prices reflect the medication itself. The consultation fee covers a personalised clinical assessment with our trained pharmacists. This assessment covers your medical history, weight loss goals, current medications, and individual suitability for Wegovy. It also includes full guidance on how to use the pen correctly and what to expect from treatment at each stage.
When comparing Wegovy prices between providers, it is important to consider what is included alongside the medication. A prescription from an online provider with minimal clinical assessment and no ongoing monitoring is not equivalent in value to a properly supported treatment programme. A properly supported programme includes a thorough initial clinical assessment, injection training, dietary and lifestyle guidance, regular progress monitoring, side effect support, and accessible professional guidance throughout treatment. The clinical support provided alongside the medication is one of the most important determinants of treatment outcomes.
What Affects the Overall Cost of Wegovy Treatment?
Several factors influence how much a patient spends on Wegovy treatment over the course of their programme. Understanding these factors in advance makes it easier to plan and budget for treatment effectively.
Dose strength is the most significant variable in monthly treatment cost. Patients begin at 0.25mg and progress through the titration schedule over approximately sixteen weeks before reaching the 2.4mg maintenance dose, where the monthly cost is highest. The monthly cost therefore increases progressively during the titration period before stabilising at the maintenance dose level. Patients who achieve excellent results at a lower maintenance dose will spend less per month than those who require the full 2.4mg dose for optimal effect.
Treatment duration also affects total cost. Wegovy is a long-term treatment rather than a short-term course. The clinical evidence consistently shows that weight regain is associated with stopping the medication if meaningful lifestyle changes have not been embedded during treatment. The length of an individual treatment programme is determined through regular clinical review with the prescribing clinician, based on the patient’s progress, health goals, and individual circumstances.
The level of clinical support included in the programme is a further consideration. Regular follow-up appointments, dietary guidance, side effect management, and accessible professional support all contribute to better outcomes. These components of care are included as standard in every treatment programme provided at J E Williamson Pharmacy in Bishops Stortford. These components of care represent genuine value that should be factored into any price comparison.
- Dose strength: monthly cost increases progressively through the titration schedule
- Treatment duration: determined through clinical review based on individual progress and health goals
- Clinical support: regular follow-up, dietary guidance, and side effect management included as standard
- Pen needles: obtained separately from the pen and priced additionally
- Consultation fee: a one-off fee covering the initial clinical assessment and pen training
How Wegovy is Administered
Injectable Wegovy is administered as a once-weekly subcutaneous injection using the Wegovy FlexTouch pen. The FlexTouch is a pre-filled multi-dose device containing four once-weekly doses of semaglutide at the prescribed strength. Unlike some injectable devices, the FlexTouch requires a compatible disposable needle to be attached before each injection. The needle must be removed and disposed of safely in a sharps container immediately after each use, before the pen is stored for the following week’s dose. The pen itself is retained for its remaining doses and disposed of after the fourth weekly injection in accordance with local guidance.
Pen needles are not supplied with the FlexTouch pen and must be obtained separately. Your prescribing pharmacy can advise on the compatible needle type and ensure you have an adequate supply before you begin treatment. All device-specific administration steps are set out in the Instructions for Use supplied with your specific pen. These should always take precedence over any general guidance from secondary sources. They include how to attach and remove the needle, how to prepare the injection site, and how to confirm the dose has been delivered correctly.
Wegovy is approved for injection at three anatomical sites: the abdomen (at least 5cm from the navel), the front of the upper thigh, and the outer upper arm. All three sites are clinically equivalent in terms of semaglutide absorption when the injection is performed correctly. Changing the injection site each week is clinically recommended to prevent repeated trauma to any single area of skin and subcutaneous tissue. J E Williamson Pharmacy in Bishops Stortford provides full FlexTouch pen training to every Wegovy patient before their first injection. This ensures every patient is confident and correctly informed before injecting at home.
Benefits and Results of Wegovy
The benefits of Wegovy extend well beyond the number on the scales, though weight loss is the primary reason most patients seek it. The STEP clinical trial programme, which formed the basis of Wegovy’s MHRA approval for weight management, demonstrated clinically meaningful average weight loss in participants with obesity across multiple study arms. These are average figures across trial populations. Individual results vary considerably depending on starting weight, dietary habits, physical activity, dose level reached, and the quality of clinical support received throughout treatment.
Beyond weight loss itself, patients frequently report a range of improvements that reflect the broader metabolic and health benefits of the medication and of meaningful weight reduction. Improvements in blood sugar control are particularly significant for patients with type 2 diabetes or insulin resistance. Reductions in blood pressure and improvements in cholesterol levels are also commonly reported in patients who achieve meaningful weight loss. Improved sleep quality and reduced joint pain, increased energy levels, and greater confidence are among the most consistently reported patient experiences as weight loss accumulates over the course of treatment.
The SELECT cardiovascular outcomes trial demonstrated a meaningful reduction in the relative risk of major cardiovascular events. The trial studied adults with established cardiovascular disease and overweight or obesity who were treated with semaglutide. This finding significantly broadens the clinical case for Wegovy beyond weight loss alone, and is particularly relevant for patients with existing cardiovascular risk factors who are considering treatment. All comparative efficacy figures should be interpreted in the context of the specific trial populations in which they were generated. A prescribing clinician can advise on individual expected outcomes based on your specific health profile.
The psychological benefits of Wegovy are reported consistently in patient accounts, even where clinical trial data does not fully capture them. Reduced food preoccupation and an improved sense of agency over food choices are described by many patients as among the most meaningful changes they experience. The ability to eat in response to genuine hunger rather than habitual or emotional drivers is consistently reported as a lasting and life-changing shift. These psychological shifts are an important part of what makes Wegovy results sustainable for patients who embed genuine lifestyle changes alongside their medication.
- Clinically meaningful average weight loss demonstrated in the STEP trial programme across multiple patient populations
- Improved blood sugar control, particularly relevant for patients with type 2 diabetes or insulin resistance
- Reductions in blood pressure and cholesterol levels associated with meaningful weight loss
- Improved sleep quality, increased energy, and reduced joint pain consistently reported as weight loss accumulates
- Meaningful reduction in cardiovascular event risk demonstrated in the SELECT outcomes trial
- Reduced food preoccupation and improved relationship with hunger and eating reported consistently by patients
To find out whether you are eligible for Wegovy treatment at J E Williamson Pharmacy in Bishops Stortford and to discuss current pricing in detail, call us to book a consultation and our clinical team will be in touch.
Safety and Who is Suitable for Wegovy
Wegovy is a prescription-only medication and requires a thorough clinical assessment before it can be prescribed. This assessment is clinically essential rather than a formality. It identifies contraindications, reviews relevant health conditions and existing medications, and confirms that Wegovy is appropriate for the individual patient. No prescription is issued at J E Williamson Pharmacy without this assessment being completed to a proper clinical standard.
Wegovy is generally considered suitable for adults with a BMI of 30 or above. It may also be appropriate for those with a BMI of 27 or above alongside a weight-related health condition. Relevant conditions include type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea. It is not appropriate for patients who are pregnant, planning a pregnancy, or breastfeeding. Patients who are planning a pregnancy should discontinue Wegovy at least two months before attempting to conceive. It is not recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is a strong clinical precaution based on findings in animal studies whose clinical relevance to humans has not been established. Patients with this history should discuss this specifically with their prescribing clinician before starting treatment.
The most commonly reported side effects of Wegovy are gastrointestinal in nature. These include nausea, vomiting, diarrhoea, and constipation. They are typically most pronounced during the early weeks of treatment and following each dose increase, and tend to improve as the body adjusts at each dose level. More serious but uncommon adverse events include pancreatitis and gallbladder disease. Signs of pancreatitis, in particular severe and persistent abdominal pain including pain that radiates to the back, require urgent medical attention. Any significant or unexpected symptoms during Wegovy treatment should be reported to your prescribing clinician or pharmacist promptly.
Wegovy vs Mounjaro
Wegovy and Mounjaro are both MHRA-licensed GLP-1 weight loss treatments and are the two most widely prescribed injectable weight loss medications in the UK. Understanding the differences between them is an important part of making an informed treatment decision. Both are available at J E Williamson Pharmacy in Bishops Stortford for eligible patients following a clinical assessment.
The most clinically significant difference is in their mechanism of action. Wegovy activates GLP-1 receptors only. Mounjaro activates both GLP-1 and GIP receptors simultaneously. This dual mechanism is associated with greater average weight loss in clinical trials, making Mounjaro the more potent treatment of the two at currently approved doses. However, these figures come from separate clinical trials with different populations and designs rather than a direct head-to-head comparison, and individual responses to each medication vary considerably.
Both medications are administered as once-weekly subcutaneous injections using multi-dose pre-filled pen devices that require needle attachment before each injection. Both are introduced through gradual titration schedules designed to minimise gastrointestinal side effects. Both work most effectively when combined with meaningful dietary and lifestyle changes. The choice between them is best made through a thorough clinical discussion with a prescribing clinician. They can assess which is most appropriate for an individual patient’s health profile, treatment goals, and personal circumstances.
- Wegovy activates GLP-1 receptors only; Mounjaro activates both GLP-1 and GIP receptors simultaneously
- Mounjaro is associated with greater average weight loss in clinical trials based on separate trial data
- Both are administered as once-weekly subcutaneous injections using multi-dose pre-filled pen devices
- Both require needle attachment before each injection and needle disposal immediately after each use
- Both work most effectively when combined with active dietary and lifestyle changes throughout treatment
- The right choice between the two depends on individual health profile and clinical assessment
The table below summarises the most important practical and clinical differences between Wegovy and Mounjaro at a glance, providing a useful reference point before discussing which treatment is most appropriate for your individual circumstances with our clinical team.
| Feature | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist only | GLP-1 and GIP receptor agonist (dual action) |
| Injectable format | Once-weekly injection using the Wegovy FlexTouch pen | Once-weekly injection using the Mounjaro KwikPen |
| Oral option | Yes; MHRA approved June 2026; must be taken on empty stomach with small amount of water 30 minutes before food | Not currently available in oral form in the UK |
| Pen device | Pre-filled multi-dose FlexTouch pen; four once-weekly doses per pen; needle attachment required per injection | Pre-filled multi-dose KwikPen; four once-weekly doses per pen; needle attachment required per injection |
| Dose strengths | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Average weight loss | Clinically meaningful; based on separate STEP trial data | Greater average weight loss than Wegovy; based on separate SURMOUNT trial data |
| Cardiovascular evidence | SELECT trial demonstrated meaningful reduction in relative risk of major cardiovascular events | Cardiovascular outcomes trial data emerging; not yet as extensive as Wegovy |
| UK availability | MHRA-licensed; available now through J E Williamson Pharmacy | MHRA-licensed; available now through J E Williamson Pharmacy |
Diet, Lifestyle and Long-Term Results
Wegovy is most effective when used as part of a comprehensive weight management approach that combines the pharmacological appetite suppression it provides with active dietary and lifestyle improvements. Clinical trial participants received dietary counselling and support alongside their medication, and the results from these trials reflect this combination rather than the medication alone.
From a dietary perspective, the most impactful changes for patients on Wegovy are prioritising protein-rich foods to preserve muscle mass and extend satiety between meals. Increasing fibre intake through vegetables, legumes, and wholegrains stabilises blood sugar levels and reduces hunger between eating occasions. Reducing ultra-processed foods and calorie-containing beverages creates a more manageable and consistent calorie deficit alongside the medication’s appetite-suppressing effects. Avoiding extreme caloric restriction is important, as very low calorie intakes during GLP-1 treatment increase the risk of muscle loss and nutritional deficiency.
Physical activity supports weight loss through increased calorie expenditure and also helps preserve muscle mass, improve metabolic rate, and support sleep quality, mood, and stress management throughout treatment. Even moderate increases in daily physical activity, such as consistent walking or building a simple home-based exercise routine, contribute meaningfully to overall outcomes over the months of treatment. Resistance training is particularly valuable for protecting lean muscle mass during a sustained calorie deficit.
Long-term maintenance of weight loss following the completion or reduction of Wegovy treatment requires the habits developed during treatment to be genuinely embedded in daily life. The clinical evidence consistently shows that weight regain is associated with stopping GLP-1 medications if lifestyle habits have not been meaningfully changed alongside treatment. This is why dietary guidance, lifestyle support, and behavioural change strategies provided by the clinical team at J E Williamson Pharmacy are integral to the treatment programme. They are not optional extras but essential components of effective, lasting weight management.
Good dietary and lifestyle habits amplify the results that Wegovy can deliver, and our calculator below can help you visualise what those amplified results could look like for your personal circumstances. Enter your height and weight below to find out your estimated weight loss potential with Wegovy or Mounjaro:
Clinical Support at J E Williamson Pharmacy in Bishops Stortford
Every Wegovy patient at J E Williamson Pharmacy in Bishops Stortford receives a standard of clinical support that goes well beyond the prescription itself. This begins with a comprehensive pre-treatment consultation. Your pharmacist reviews your medical history, assesses your suitability for Wegovy, discusses your weight loss goals, and explains what to expect at every stage. Full FlexTouch pen training is provided before your first injection. This ensures you are confident and correctly informed about needle attachment, injection site selection, dose confirmation, needle disposal, and pen storage before injecting at home.
Throughout your treatment, the clinical team is available to answer questions and support the management of any side effects that arise. They monitor your progress at regular review appointments and adjust dietary and lifestyle recommendations as your treatment evolves. Dose escalation decisions are reviewed clinically rather than following the standard schedule by default, ensuring that the pace of titration is appropriate for your individual tolerability and response. Any concerns that arise between scheduled appointments can be raised with the team directly, ensuring that professional support is consistently accessible throughout your entire treatment journey.
Patients who access Wegovy through a properly regulated, well-monitored clinical service consistently achieve better outcomes than those who use medication with minimal oversight. The quality and accessibility of clinical support throughout treatment is one of the most important determinants of both the pace of results and their long-term sustainability. All Wegovy medication supplied through J E Williamson Pharmacy is obtained from licensed UK pharmaceutical suppliers. Patients should always access Wegovy through a GPhC-registered pharmacy with a properly regulated prescribing process. Obtaining prescription weight loss medication from unregulated online sources carries significant risks of counterfeit or substandard products.
Frequently Asked Questions
The clinical team at J E Williamson Pharmacy in Bishops Stortford has compiled clear, honest answers to the Wegovy questions that patients raise most regularly before and during treatment.
Your Wegovy Journey Begins Here
Wegovy is one of the most established and effective prescription weight loss treatments available in the UK, with a comprehensive evidence base and years of real-world prescribing experience behind it. J E Williamson Pharmacy in Bishops Stortford provides a fully supported, properly assessed treatment programme. Our goal is to give every eligible patient the best possible chance of achieving safe, meaningful, and lasting results. From your initial assessment and pen training through to ongoing monitoring and dietary guidance, our clinical team is here throughout your entire Wegovy journey.
If you’re considering Wegovy, book a consultation with our team in Bishops Stortford and find out whether Wegovy is right for you.
Disclaimer: The information on this page is intended for general informational purposes only and does not constitute medical advice. Wegovy (semaglutide) is a prescription-only medication that requires a thorough clinical assessment before prescribing. Always read the Instructions for Use supplied with your Wegovy pen and follow the specific guidance provided by your prescribing clinician or pharmacist. Always speak to a qualified medical professional before starting, changing, or stopping any treatment. Individual results and suitability for treatment will vary.
